Diligence memo · auto-generated · as of July 3, 2026
Kamau Therapeutics, Inc.
Kamau Therapeutics, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Kamau Therapeutics, Inc. operates in Pharma, based in SOUTH SAN FRANCISCO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Kamau Therapeutics, Inc. has raised $5.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.0M on 2025-05-19.
Most recent recorded round closed around 2025-05-19.
Valuation (modeled)modeled
Provath models Kamau Therapeutics, Inc. at approximately $17M (range $5.7M–$31M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.13× the median modeled value of Series A Pharma companies in 2025–2027 (9 peers) — value vs value, same stage and era. Within the normal band (113% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 13 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 54% of Pharma peers (310 compared).
Modeled value ranks above 42% of those peers.
Closest niche peers: Neela Therapeutics, Inc., AeroRx Therapeutics, Inc., Cirrus Therapeutics, Inc., Merge Bio Therapeutics Corp, PanTher Therapeutics, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.